Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.

A novel avian influenza A H7N9-subtype virus emerged in China in 2013 and threatened global public health. Commercial kits that specifically detect avian influenza A (H7N9) virus RNA are urgently required to prepare for the emergence and potential pandemic of this novel influenza virus. The safety a...

Full description

Bibliographic Details
Main Authors: Dawei Shi, Shu Shen, Xingliang Fan, Suhong Chen, Dayan Wang, Changgui Li, Xing Wu, Lili Li, Dongting Bai, Chuntao Zhang, Junzhi Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4567293?pdf=render
_version_ 1819168810704306176
author Dawei Shi
Shu Shen
Xingliang Fan
Suhong Chen
Dayan Wang
Changgui Li
Xing Wu
Lili Li
Dongting Bai
Chuntao Zhang
Junzhi Wang
author_facet Dawei Shi
Shu Shen
Xingliang Fan
Suhong Chen
Dayan Wang
Changgui Li
Xing Wu
Lili Li
Dongting Bai
Chuntao Zhang
Junzhi Wang
author_sort Dawei Shi
collection DOAJ
description A novel avian influenza A H7N9-subtype virus emerged in China in 2013 and threatened global public health. Commercial kits that specifically detect avian influenza A (H7N9) virus RNA are urgently required to prepare for the emergence and potential pandemic of this novel influenza virus. The safety and effectiveness of three commercial molecular diagnostic assays were evaluated using a quality-control panel and clinical specimens collected from over 90 patients with confirmed avian influenza A (H7N9) virus infections. The analytical performance evaluation showed that diverse influenza H7N9 viruses can be detected with high within- and between-lot reproducibility and without cross-reactivity to other influenza viruses (H1N1 pdm09, seasonal H1N1, H3N2, H5N1 and influenza B). The detection limit of all the commercial assays was 2.83 Log10 copies/μl [0.7 Log10TCID50/mL of avian influenza A (H7N9) virus strain A/Zhejiang/DTID-ZJU01/2013], which is comparable to the method recommended by the World Health Organization (WHO). In addition, using a WHO-Chinese National Influenza Center (CNIC) method as a reference for clinical evaluation, positive agreement of more than 98% was determined for all of the commercial kits, while negative agreement of more than 99% was observed. In conclusion, our findings provide comprehensive evidence for the high performance of three commercial diagnostic assays and suggest the application of these assays as rapid and effective diagnostic tools for avian influenza A (H7N9) virus in the routine clinical practice of medical laboratories.
first_indexed 2024-12-22T19:09:31Z
format Article
id doaj.art-d23f951890b64faa962eded4fb08b7e6
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-22T19:09:31Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-d23f951890b64faa962eded4fb08b7e62022-12-21T18:15:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01109e013786210.1371/journal.pone.0137862Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.Dawei ShiShu ShenXingliang FanSuhong ChenDayan WangChanggui LiXing WuLili LiDongting BaiChuntao ZhangJunzhi WangA novel avian influenza A H7N9-subtype virus emerged in China in 2013 and threatened global public health. Commercial kits that specifically detect avian influenza A (H7N9) virus RNA are urgently required to prepare for the emergence and potential pandemic of this novel influenza virus. The safety and effectiveness of three commercial molecular diagnostic assays were evaluated using a quality-control panel and clinical specimens collected from over 90 patients with confirmed avian influenza A (H7N9) virus infections. The analytical performance evaluation showed that diverse influenza H7N9 viruses can be detected with high within- and between-lot reproducibility and without cross-reactivity to other influenza viruses (H1N1 pdm09, seasonal H1N1, H3N2, H5N1 and influenza B). The detection limit of all the commercial assays was 2.83 Log10 copies/μl [0.7 Log10TCID50/mL of avian influenza A (H7N9) virus strain A/Zhejiang/DTID-ZJU01/2013], which is comparable to the method recommended by the World Health Organization (WHO). In addition, using a WHO-Chinese National Influenza Center (CNIC) method as a reference for clinical evaluation, positive agreement of more than 98% was determined for all of the commercial kits, while negative agreement of more than 99% was observed. In conclusion, our findings provide comprehensive evidence for the high performance of three commercial diagnostic assays and suggest the application of these assays as rapid and effective diagnostic tools for avian influenza A (H7N9) virus in the routine clinical practice of medical laboratories.http://europepmc.org/articles/PMC4567293?pdf=render
spellingShingle Dawei Shi
Shu Shen
Xingliang Fan
Suhong Chen
Dayan Wang
Changgui Li
Xing Wu
Lili Li
Dongting Bai
Chuntao Zhang
Junzhi Wang
Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.
PLoS ONE
title Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.
title_full Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.
title_fullStr Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.
title_full_unstemmed Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.
title_short Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China.
title_sort evaluation of commercial diagnostic assays for the specific detection of avian influenza a h7n9 virus rna using a quality control panel and clinical specimens in china
url http://europepmc.org/articles/PMC4567293?pdf=render
work_keys_str_mv AT daweishi evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT shushen evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT xingliangfan evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT suhongchen evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT dayanwang evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT changguili evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT xingwu evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT lilili evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT dongtingbai evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT chuntaozhang evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina
AT junzhiwang evaluationofcommercialdiagnosticassaysforthespecificdetectionofavianinfluenzaah7n9virusrnausingaqualitycontrolpanelandclinicalspecimensinchina